Nektar Therapeutics

Bladder cancer readout sees Nektar shares hit
Bladder cancer readout sees Nektar shares hit
Fierce Biotech
Nektar Therapeutics
bladder cancer
NKTR-214
Opdivo
Bristol-Myers Squibb
Flag link:
Here's Why Nektar Therapeutics Surged Today
Here's Why Nektar Therapeutics Surged Today
Motley Fool
Nektar Therapeutics
JPMHC 2019
NKTR-214
Flag link:
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
Xconomy
clinical trials
Alzheimer's disease
Biogen
Duchenne Muscular Dystrophy
Pfizer
Solid Biosciences
Sarepta Therapeutics
hemophilia A
Biomarin
Multiple Myeloma
Celgene
Bluebird Bio
Amgen
solid tumors
Bristol-Myers Squibb
Nektar Therapeutics
age-related macular degeneration
Regenxbio
SAGE Therapeutics
MorphoSys
Flag link:
Pfizer's PARP, androgen inhibitors next combo partners for NKTR-214
Pfizer's PARP, androgen inhibitors next combo partners for NKTR-214
BioCentury
Pfizer
Nektar Therapeutics
NKTR-214
Xtandi
Talzenna
Bavencio
prostate cancer
Flag link:
Did Bristol-Myers Squibb Make a Huge Mistake With Nektar?
Did Bristol-Myers Squibb Make a Huge Mistake With Nektar?
Motley Fool
Bristol-Myers Squibb
Nektar Therapeutics
NKTR-2014
Flag link:
Nektar’s long-acting IL-2 NKTR-214 has 'zero value,' claims analyst
Nektar’s long-acting IL-2 NKTR-214 has 'zero value,' claims analyst
Fierce Biotech
Nektar Therapeutics
NKTR-214
Flag link:
The opioid drug that addicts don't like could be approved next spring
The opioid drug that addicts don't like could be approved next spring
Bizjournals.com
Nektar Therapeutics
NKTR-181
opioids
opiod crisis
Flag link:
#ASCO18: A Weekend of Surprises
#ASCO18: A Weekend of Surprises
Motley Fool
ASCO 2018
Bluebird Bio
Loxo Oncology
Nektar Therapeutics
Celgene
Grail
Flag link:
Winners and Losers From the Biggest Cancer Meeting of the Year (So Far)
Winners and Losers From the Biggest Cancer Meeting of the Year (So Far)
Motley Fool
ASCO
Endocyte
Loxo Oncology
Blueprint Medicines
Nektar Therapeutics
Jounce Therapeutics
Flag link:
Nektar begins Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 With CD122-Biased Agonist NKTR-214 in Patients With Advanced Solid Tumors
Nektar begins Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 With CD122-Biased Agonist NKTR-214 in Patients With Advanced Solid Tumors
CP Wire
Nektar Therapeutics
NKTR-214
NKTR-262
cancer
solid tumors
Flag link:
How a Biotech Bummer Sent Nektar Therapeutics Stock South Today
How a Biotech Bummer Sent Nektar Therapeutics Stock South Today
Motley Fool
Nektar Therapeutics
Incyte
Merck
NKTR-214
Bristol-Myers Squibb
Flag link:
Can Bristol-Myers Squibb Squeeze $3.6 Billion From Its Nektar Therapeutics Deal?
Can Bristol-Myers Squibb Squeeze $3.6 Billion From Its Nektar Therapeutics Deal?
Motley Fool
Bristol-Myers Squibb
M&A
Nektar Therapeutics
Flag link:
Bristol-Myers To Pay Largest Fee In Biotech History For Nektar Cancer Drug
Bristol-Myers To Pay Largest Fee In Biotech History For Nektar Cancer Drug
Forbes
Bristol-Myers Squibb
Nektar Therapeutics
NKTR-214
cancer
Flag link:
Nektar Therapeutics reportedly considering a sale
Nektar Therapeutics reportedly considering a sale
Fierce Biotech
Nektar Therapeutics
M&A
Flag link: